{
    "nctId": "NCT01572038",
    "briefTitle": "A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer",
    "officialTitle": "A Multicenter, Open-Label, Single-Arm Study of Pertuzumab in Combination With Trastuzumab and a Taxane in First Line Treatment of Patients With HER2-Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 1436,
    "primaryOutcomeMeasure": "Overview of the Number of Participants With at Least One Treatment-Emergent Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v4.0)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed adenocarcinoma of the breast with metastatic or locally recurrent disease not amenable to curative resection\n* HER2-positive breast cancer\n* Eastern cooperative Oncology Group (ECOG) performance status 0, 1 or 2\n* LVEF of at least 50 percent (%)\n\nExclusion Criteria:\n\n* Previous systemic non-hormonal anti-cancer therapy for metastatic or locally recurrent disease\n* Disease-free interval from completion of adjuvant or neoadjuvant systemic non-hormonal treatment to recurrence less than or equal to (\\</=) 6 months\n* Previous approved or investigative anti-HER2 agents in any breast cancer treatment setting, except for trastuzumab and/or lapatinib in the adjuvant or neoadjuvant setting\n* Disease progression while receiving trastuzumab and/or lapatinib in the adjuvant or neoadjuvant setting\n* History of persistent Grade 2 or higher (National Cancer Institute Common Toxicity Criteria \\[NCI-CTC\\], Version 4.0) hematological toxicity resulting from previous adjuvant or neoadjuvant therapy\n* Central nervous system (CNS) metastases\n* Current peripheral neuropathy of Grade 3 or greater (NCI-CTC, version 4.0)\n* History of other malignancy within the last 5 years prior to first study drug administration, except for carcinoma in situ of the cervix or basal cell carcinoma\n* Inadequate bone marrow, liver or renal function\n* Uncontrolled hypertension\n* Hepatitis B, hepatitis C or Human Immunodeficiency Virus (HIV) infection",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}